



March 10, 2015

Aldeyra Therapeutics Schedules Webcast and Conference Call for Fourth Quarter 2014 Financial Results

LEXINGTON, Mass., March 10, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it will issue its financial results for the fourth quarter and twelve months ended December 31, 2014 on Thursday, March 19, 2015, prior to the market open.

Aldeyra will hold a conference call on Thursday, March 19, 2015, at 8:30 a.m. ET. Dr. Todd Brady, President and Chief Executive Officer, and Stephen Tulipano, Chief Financial Officer, will host the conference call to discuss Aldeyra's financial results for the fourth quarter and twelve months ended December 31, 2014 and provide a general corporate update. The dial-in numbers are 1-877-407-0784 for domestic callers and 1-201-689-8560 for international callers. The conference ID number for both is 13603960. A live webcast of the conference call will also be available on the investor relations page of Aldeyra's corporate website at www.aldeyra.com.

After the live webcast, the event will remain archived on Aldeyra's website for one year. In addition, a telephonic replay of the call will be available until April 2, 2015. The replay dial-in numbers are 1-877-870-5176 for domestic callers and 1-858-384-5517 for international callers. Please use event passcode 13603960.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to initiate Phase II clinical studies of NS2 in Sjögren-Larsson Syndrome and noninfectious anterior uveitis in 2015. NS2 has not been approved for sale in the U.S. or elsewhere. www.aldeyra.com

CONTACT: Corporate Contact:

Stephen Tulipano

Aldeyra Therapeutics, Inc.

Tel: +1 781-761-4904 ext. 205

stulipano@aldeyra.com

Investor Contact:

David Burke/Lee Roth

The Ruth Group

Tel: +1 646-536-7009/7012

dburke@theruthgroup.com/lroth@theruthgroup.com

Source: Aldeyra Therapeutics

News Provided by Acquire Media